These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 2685142

  • 1. [Clinical studies of long-term administration of OK-432 in patients with gynecologic cancer].
    Mano T, Kawamoto K, Miyake T, Torigoe T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1439-45. PubMed ID: 2685142
    [Abstract] [Full Text] [Related]

  • 2. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)].
    Shiraishi T, Nio Y, Imai S, Tsubono M, Morimoto H, Tseng CC, Tobe T, Tanaka T, Kitamura O, Sakanashi S.
    Nihon Gan Chiryo Gakkai Shi; 1990 Apr 20; 25(4):799-811. PubMed ID: 2196311
    [Abstract] [Full Text] [Related]

  • 3. [Immunochemotherapy of resectable lung cancer--a preliminary study on a comparison of the control, levamisole, and OK-432].
    Okayasu T, Kashimura Y, Matano J, Kawabata M, Takeoka T, Hashimoto M, Tanabe T.
    Gan To Kagaku Ryoho; 1982 Sep 20; 9(9):1646-52. PubMed ID: 6764120
    [Abstract] [Full Text] [Related]

  • 4. [Adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer].
    Kikkawa N, Sasai H, Kawahara T.
    Gan To Kagaku Ryoho; 1984 Oct 20; 11(10):2163-9. PubMed ID: 6486832
    [Abstract] [Full Text] [Related]

  • 5. Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer.
    Kimura T, Suzuki K, Motai H, Miyamoto N, Tsuge I, Ito Y, Baba S.
    Acta Otolaryngol Suppl; 1996 Oct 20; 525():135-41. PubMed ID: 8908288
    [Abstract] [Full Text] [Related]

  • 6. [The clinical value of long-term administration of OK-432 in head and neck cancer].
    Mitarai K, Tsukuda M, Tamamushi N, Mochimastu I, Kubota A, Sawaki S.
    Gan To Kagaku Ryoho; 1986 Apr 20; 13(4 Pt 1):945-50. PubMed ID: 3963858
    [Abstract] [Full Text] [Related]

  • 7. [Randomized controlled study of OK-432 in the treatment of cancerous pleurisy].
    Urata A, Nishimura M, Ota K.
    Gan To Kagaku Ryoho; 1983 Jun 20; 10(6):1497-503. PubMed ID: 6409006
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [A controlled study of surgical adjuvant chemoimmunotherapy with FT-207 and OK-432 for advanced stomach cancer: the fourth study].
    Yamamura Y, Yasue M, Nakazato H, Ota K.
    Gan To Kagaku Ryoho; 1985 Mar 20; 12(3 Pt 1):541-8. PubMed ID: 3923941
    [Abstract] [Full Text] [Related]

  • 10. [Studies on the enhancement of anti-tumor activity in patients with cervical cancer by local administration of OK-432].
    Yamada Y, Yamamoto K, Wakita K, Shiraki S, Noda K.
    Gan To Kagaku Ryoho; 1986 Dec 20; 13(12):3427-31. PubMed ID: 3789753
    [Abstract] [Full Text] [Related]

  • 11. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)].
    Shiraishi T, Nio Y, Imai S, Tsubono M, Morimoto H, Tseng CC, Tobe T, Tanaka T, Kitamura O, Sakanashi S.
    Nihon Gan Chiryo Gakkai Shi; 1990 May 20; 25(5):997-1012. PubMed ID: 2202770
    [Abstract] [Full Text] [Related]

  • 12. [Effect of endoscopical administration of OK-432 in 4 patients with advanced esophageal or gastric cancer].
    Satomi T, Inoue S, Fujita T, Ogawa S, Honda H, Hayashi M.
    Gan No Rinsho; 1989 Mar 20; 35(4):512-5. PubMed ID: 2541269
    [Abstract] [Full Text] [Related]

  • 13. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer.
    Watanabe Y, Iwa T.
    J Biol Response Mod; 1987 Apr 20; 6(2):169-80. PubMed ID: 3585412
    [Abstract] [Full Text] [Related]

  • 14. [The effect of OK-432 in the treatment of primary lung cancer].
    Kishimoto T, Okada K.
    Gan To Kagaku Ryoho; 1987 Apr 20; 14(4):1051-6. PubMed ID: 3494430
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [New combined therapy of radiation and local administration of OK-432 for esophageal cancer--local control rate and two-year survival rate].
    Mukai M, Morita S, Tsunemoto H.
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan 20; 25(1):94-7. PubMed ID: 2324590
    [Abstract] [Full Text] [Related]

  • 19. Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cervical Cancer Immunotherapy Study Group.
    Noda K, Teshima K, Tekeuti K, Hasegawa K, Inoue K, Yamashita K, Sawaragi I, Nakajima T, Takashima E, Ikeuchi M.
    Gynecol Oncol; 1989 Dec 20; 35(3):367-72. PubMed ID: 2689304
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.